anti-galectin-9 monoclonal antibody LYT-200

A human immunoglobulin G4 (IgG4) monoclonal antibody directed against the immunosuppressive protein galectin-9, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-galectin-9 monoclonal antibody LYT-200 targets, binds to and blocks galectin-9 on tumor cells which prevents galectin-9-mediated signaling. This may abrogate activation of immunosuppressive signaling pathways in the tumor microenvironment (TME) and may activate a cytotoxic T-lymphocyte (CTL)-mediated immune response against the galectin-9-expressing tumor cells. Galectin-9, overexpressed on a variety of tumor cells, plays a key role in cancer cell proliferation and evasion of immune responses. Its expression is correlated with decreased patient survival.